Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib therapeutic drug monitoring with intrapatient dose escalation in renal cell carcinoma
2012-002962-11Phase 2Terminated
- Sponsor
- I-QUO
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pazopanib in renal cell carcinoma (RCC) (2 arms), sponsored by I-QUO. Primary endpoint: Fraction of low plasma level patients achieving target pazopanib trough concentration. Started Mar 2013; status: terminated.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2012-002962-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002962-11.